LeMaitre Vascular (NASDAQ:LMAT) Upgraded at Freedom Capital

LeMaitre Vascular (NASDAQ:LMAT) was upgraded by analysts at Freedom Capital to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

LMAT has been the topic of several other research reports. Weiss Ratings raised LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, March 10th. Roth Mkm restated a “buy” rating and issued a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Citizens Jmp raised their price target on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 26th. Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Barrington Research increased their target price on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $105.80.

LeMaitre Vascular Stock Down 0.4%

LeMaitre Vascular stock opened at $108.75 on Tuesday. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of 43.33, a PEG ratio of 3.14 and a beta of 0.67. The company’s 50 day simple moving average is $98.21 and its 200 day simple moving average is $90.43. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. The firm had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The business’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, sell-side analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current year.

Insider Buying and Selling

In related news, Director David B. Roberts sold 8,464 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the completion of the transaction, the director directly owned 17,979 shares in the company, valued at approximately $1,920,157.20. This trade represents a 32.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 150,000 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $106.76, for a total value of $16,014,000.00. Following the completion of the sale, the chief executive officer owned 1,532,304 shares in the company, valued at $163,588,775.04. The trade was a 8.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 215,438 shares of company stock worth $23,062,911. 9.50% of the stock is owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

Institutional investors have recently made changes to their positions in the business. Advisors Asset Management Inc. grew its position in LeMaitre Vascular by 3.0% in the second quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock valued at $341,000 after purchasing an additional 118 shares in the last quarter. Illinois Municipal Retirement Fund boosted its stake in shares of LeMaitre Vascular by 1.1% during the 4th quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after buying an additional 123 shares during the last quarter. NewEdge Advisors LLC grew its holdings in shares of LeMaitre Vascular by 4.6% in the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after acquiring an additional 139 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in shares of LeMaitre Vascular by 1.2% in the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock valued at $971,000 after acquiring an additional 147 shares in the last quarter. Finally, Johnson Investment Counsel Inc. increased its position in shares of LeMaitre Vascular by 0.5% in the third quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock valued at $2,607,000 after acquiring an additional 153 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.